Division of Hematology and Oncology

P. Brent Ferrell, MD, is part of a multidisciplinary team studying new approaches to understand and treat cancer.
March 17, 2022

Ferrell lands Mark Foundation for Cancer Research award

Vanderbilt’s Brent Ferrell, MD, is one of the recipients a 2022 Endeavor Award from the The Mark Foundation for Cancer Research.

By Tom Wilemon
March 7, 2022

Study finds World Trade Center responders at higher risk for blood cancer-associated mutations

A study by Vanderbilt and New York City researchers found that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease

By Tom Wilemon
February 17, 2022

Park named director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, deputy director of the Vanderbilt-Ingram Cancer Center, has been named the center’s new director.

By John Howser
February 17, 2022

Grant to support Haake’s research on kidney cancer

Kure It Cancer Research has awarded a $200,000 grant to support kidney cancer research by Vanderbilt’s Scott Haake, MD.

By Tom Wilemon
January 25, 2022

Comprehensive framework outlined for addressing early-onset colorectal cancer research

New research from Vanderbilt sets a comprehensive framework for addressing research challenges and patient needs for people under 50 with colorectal cancer.

By Tom Wilemon
December 24, 2021

Study of fully vaccinated patients with cancer who had breakthrough COVID-19 shows 13% mortality rate

New research finds that fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death.

By Tom Wilemon
December 21, 2021

New Clinician Spotlight: Katherine Walsh

Katherine Walsh, MD, has joined Vanderbilt University Medical Center as associate professor of Medicine in the Division of Hematology and Oncology.
By VUMC News and Communications
December 9, 2021

Cell signaling targets in leukemia

Vanderbilt researchers identified a critical role for IL-1beta signaling in leukemia cells with a certain mutation, suggesting this pathway may be a good target for novel treatments.
By Leigh MacMillan
November 2, 2021

Shifts in neuroendocrine cancer clinical trial design

Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.
By Leigh MacMillan
September 23, 2021

Eng named co-chair of NCI clinical trials steering committee

Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.
By Tom Wilemon
September 10, 2021

Novel immunotherapy shows robust response for multiple myeloma

Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.
By Tom Wilemon
August 19, 2021

Park named to new role as deputy director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, Cornelius Abernathy Professor of Medicine, has been named deputy director of Vanderbilt-Ingram Cancer Center (VICC).
By Tom Wilemon
August 12, 2021

Study identifies biomarker for breast cancer response to immunotherapy

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
By Tom Wilemon
1 … 4 5 6 7 8 … 16